olmesartan medoxomil has been researched along with Body Weight in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 14 (77.78) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhury, H; Gorain, B; Jaisankar, P; Karan, S; Pal, TK; Tekade, RK | 1 |
| Baulmann, J; Becker, ST; Dahlöf, B; Kaschina, E; Lucht, K; Paulis, L; Schwengel, K; Slavic, S; Steckelings, UM; Thöne-Reineke, C; Unger, T | 1 |
| Adachi, Y; Fukamizu, A; Garbers, DL; Harada, M; Izumi, T; Kawakami, R; Kishimoto, I; Kuwahara, K; Li, Y; Nakagawa, Y; Nakanishi, M; Nakao, K; Saito, Y; Takahashi, N; Tanimoto, K | 1 |
| Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H | 1 |
| Abe, Y; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Miyata, K; Miyatake, A; Nagai, Y; Nishiyama, A; Ozawa, Y; Shokoji, T; Yao, L; Yukimura, T | 1 |
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Hasegawa, K; Kishimoto, C; Kita, T; Nimata, M; Okabe, TA; Shioji, K; Yuan, Z | 1 |
| Inoue, H; Takeuchi, M; Yamagishi, S | 1 |
| Fukushima, Y; Kato, M; Koike, H; Mizuno, M; Sada, T; Terashima, H | 1 |
| Ichikawa, K; Konta, T; Kubota, I; Takahashi, T; Takasaki, S; Takeishi, Y | 1 |
| Ikeda, M; Ito, K; Ito, KM; Kato, T; Nasu, T; Sonoda, H | 1 |
| Gong, HP; Li, L; Ma, ZY; Song, T; Tan, HW; Wang, ZH; Zhang, W; Zhang, Y; Zhong, M; Zhong, XZ | 1 |
| Egashira, K; Kitabatake, A; Okamoto, H; Shimokawa, H; Sueishi, K; Takemoto, M; Takeshita, A; Tomita, H; Usui, M | 1 |
| Harada, N; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S | 1 |
| Higashiura, K; Li, Y; Shimamoto, K; Takada, M; Takada, T; Takizawa, H; Togashi, N; Torii, T; Ura, N | 1 |
| Higashiura, K; Murakami, H; Shimamoto, K; Togashi, N; Ura, N | 1 |
| Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Minamino, T; Node, K; Ogai, A; Ogita, H; Sakata, Y; Sanada, S; Takashima, S; Yamada, J | 1 |
| Kato, M; Koike, H; Mizuno, M; Sada, T | 1 |
1 trial(s) available for olmesartan medoxomil and Body Weight
| Article | Year |
|---|---|
Possible beneficial effect of olmesartan medoxomil on left atrial function in patients with hypertension : noninvasive assessment by acoustic quantification.
Topics: Acoustics; Angiotensin II Type 1 Receptor Blockers; Atrial Function, Left; Blood Pressure; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Outpatients; Patient Dropouts; Tetrazoles; Time Factors | 2008 |
17 other study(ies) available for olmesartan medoxomil and Body Weight
| Article | Year |
|---|---|
Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Body Weight; Brain; Chromatography, Liquid; Drinking; Drug Carriers; Drug Compounding; Eating; Emulsions; Male; Nanomedicine; Nanoparticles; Oils; Olmesartan Medoxomil; Organ Size; Permeability; Rats, Wistar; Reproducibility of Results; Risk Assessment; Tandem Mass Spectrometry; Tissue Distribution; Toxicity Tests, Subchronic; Water | 2016 |
Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Flow Velocity; Blood Pressure; Body Weight; Collagen; Disease Models, Animal; Hydroxyproline; Hypertension; Imidazoles; Male; NG-Nitroarginine Methyl Ester; Olmesartan Medoxomil; Pulsatile Flow; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Sulfonamides; Tetrazoles; Thiophenes; Vascular Stiffness | 2012 |
Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Fibrosis; Gene Targeting; Guanylate Cyclase; Heart Rate; Heart Ventricles; Hypertension; Imidazoles; Mice; Mice, Knockout; Myocardium; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Organ Size; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Atrial Natriuretic Factor; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Ventricular Remodeling | 2002 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Hydralazine; Hypertension, Renal; Imidazoles; Immunohistochemistry; In Vitro Techniques; Kidney; Lipids; Lysine; Male; Olmesartan Medoxomil; Oxidation-Reduction; Proteinuria; Rats; Tetrazoles | 2003 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Hydralazine; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; NADPH Oxidases; Olmesartan Medoxomil; Prediabetic State; Rats; Rats, Inbred OLETF; Receptors, Angiotensin; Renin; Tetrazoles; Thiazepines; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta | 2005 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoimmune Diseases; Blood Pressure; Body Weight; Cardiomyopathies; Disease Models, Animal; Heart Failure; Heart Rate; Imidazoles; Interleukin-1; Lymphocytes; Myocarditis; Myocardium; Myosins; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Tetrazoles | 2005 |
Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.
Topics: Acetylglucosamine; Angiotensin II Type 2 Receptor Blockers; Animals; Body Weight; Glomerulosclerosis, Focal Segmental; Glycation End Products, Advanced; Imidazoles; Kidney Diseases; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; Tetrazoles; Tissue Fixation | 2005 |
The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Chemokine CCL2; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Imidazoles; Immunohistochemistry; Kidney Failure, Chronic; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Serum Albumin; Survival Rate; Systole; Tetrazoles | 2006 |
An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Imidazoles; Immunohistochemistry; Kidney; Kidney Glomerulus; Lipid Metabolism; Lipid Peroxidation; Male; Nephrectomy; Olmesartan Medoxomil; Organ Size; Proteins; Rats; Rats, Wistar; Renal Insufficiency; Tetrazoles | 2007 |
Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imidazoles; Lung; Male; Monocrotaline; Olmesartan Medoxomil; Pulmonary Artery; Rats; Rats, Wistar; Tetrazoles; Time Factors | 2008 |
Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Bradykinin; Cardiomegaly; Coronary Vessels; Fibrosis; Heart; Heart Rate; Imidazoles; Male; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Olmesartan Medoxomil; Peptidyl-Dipeptidase A; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Thiazepines | 1997 |
Cilnidipine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous NIDDM.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Tolerance Test; Imidazoles; Insulin; Insulin Resistance; Lipid Metabolism; Male; Olmesartan Medoxomil; Rats; Rats, Inbred OLETF; Tetrazoles; Time Factors | 1999 |
The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Dietary Carbohydrates; Fasting; Fructose; Glucose; Glucose Clamp Technique; Heart Rate; Hypertension; Imidazoles; Insulin Resistance; Magnesium; Male; Muscle Fibers, Fast-Twitch; Muscle Fibers, Skeletal; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Olmesartan Medoxomil; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiazepines | 2000 |
The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Epididymis; Fructose; Glucose Clamp Technique; Heart Rate; Hypertension; Imidazoles; Insulin Resistance; Male; Muscle, Skeletal; Olmesartan Medoxomil; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiazepines; Tumor Necrosis Factor-alpha | 2000 |
Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Cardiomegaly; Coronary Vessels; Enalapril; Enzyme Inhibitors; Heart Rate; Heart Ventricles; Imidazoles; Losartan; Male; Mitogen-Activated Protein Kinases; Myocardium; Neutrophil Infiltration; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Ribosomal Protein S6 Kinases; Tetrazoles; Thiazepines | 2001 |
Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Imidazoles; Insulin; Kidney; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Inbred Strains; Rats, Zucker; Receptor, Angiotensin, Type 1; Serum Albumin; Tetrazoles | 2002 |